Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Topical application without delivery enhancement deposits the molecule on the outermost stratum corneum (10 to 20 micrometers thick), which is the wrong tissue for the receptor biology to engage 2
PLoS One 11 , e0160555
However, some secondary measures of nerve impairment did improve, especially in participants with higher cardiovascular risk and moderate BMI.7 Shorter-term trials have shown that 600mg/day of oral racemic ALA reduced neuropathy symptoms like burning, tingling, and numbness in as little as 35 weeks.4 20 A 2010 meta-analysis concluded that oral ALA can improve symptoms of diabetic neuropathy, but noted variability in effect sizes across trials and better results with intravenous administration.1 Despite promising results from some trials, a recent systematic review evaluating eight randomized controlled trials indicates that findings on ALA's effectiveness in treating diabetic neuropathy symptoms are inconsistent.23 While ALA proved safe and tolerable across these studies, the review concluded that definitive evidence supporting significant benefits is limited
Chouinard, V
RESEARCH USE ONLY NOT FOR HUMAN CONSUMPTION NOT APPROVED BY MHRA LABORATORY USE ONLY 18+ ONLY BPC-157 Body Protection Compound pentadecapeptide for research use Certificate Available HPLC Verified Temperature Controlled RESEARCH USE ONLY - This product is strictly for laboratory research purposes only
The phase 2 and phase 3 trials focused primarily on total body weight reduction
